Trial Profile
A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs TAS 119 (Primary)
- Indications Adenocarcinoma; Adrenocortical carcinoma; Advanced breast cancer; Chondrosarcoma; Colorectal cancer; Endocrine gland neoplasms; Endometrial cancer; Gastric cancer; Head and neck cancer; Lung cancer; Mesothelioma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Taiho Pharmaceutical
- 06 Oct 2020 Results published in the British Journal of Cancer
- 18 Feb 2020 Status changed from active, no longer recruiting to discontinued.
- 04 Jun 2019 Results assessing safety and tolerability of TAS-119 in patients with advanced solid tumors, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.